Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation

Dingyuan Luo, Magdalena Fraga-Lauhirat, Jonathan Millings, Cristella Ho, Emily M. Villarreal, Teresa C. Fletchinger, James V. Bonfiglio, Leyda Mata, Matthew D. Nemesure, Lauren E. Bartels, Ruixue Wang, Basil Rigas, Gerardo G. Mackenzie

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

New therapeutic strategies against glioblastoma multiforme (GBM) are urgently needed. Signal transducer and activator of transcription 3 (STAT3), constitutively active in many GBM tumors, plays a major role in GBM tumor growth and represents a potential therapeutic target. We have documented previously that phospho-valproic acid (MDC-1112), which inhibits STAT3 activation, possesses strong anticancer properties in multiple cancer types. In this study, we explored the anticancer efficacy of MDC-1112 in preclinical models of GBM, and evaluated its mode of action. MDC-1112 inhibited the growth of multiple human GBM cell lines in a concentration- and time-dependent manner. Normal human astrocytes were resistant to MDC-1112, indicating selectivity. In vivo, MDC-1112 reduced the growth of subcutaneous GBM xenografts in mice by up to 78.2% (P < 0.01), compared with the controls. Moreover, MDC-1112 extended survival in an intracranial xenograft model. Although all vehicle-treated mice died by 19 days of treatment, 7 of 11 MDC-1112-treated mice were alive and healthy by the end of 5 weeks, with many showing tumor regression. Mechanistically, MDC-1112 inhibited STAT3 phosphorylation at the serine 727 residue, but not at tyrosine 705, in vitro and in vivo. STAT3 overexpression rescued GBM cells from the cell growth inhibition by MDC-1112. In addition, MDC-1112 reduced STAT3 levels in the mitochondria and enhanced mitochondrial levels of reactive oxygen species, which triggered apoptosis. In conclusion, MDC-1112 displays strong efficacy in preclinical models of GBM, with the serine 727 residue of STAT3 being its key molecular target. MDC-1112 merits further evaluation as a drug candidate for GBM. New therapeutic options are needed for glioblastoma. The novel agent MDC-1112 is an effective anticancer agent in multiple animal models of glioblastoma, and its mechanism of action involves the inhibition of STAT3 phosphorylation, primarily at its Serine 727 residue.

Original languageEnglish (US)
Pages (from-to)1480-1491
Number of pages12
JournalCarcinogenesis
Volume40
Issue number12
DOIs
StatePublished - Dec 31 2019

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation'. Together they form a unique fingerprint.

  • Cite this

    Luo, D., Fraga-Lauhirat, M., Millings, J., Ho, C., Villarreal, E. M., Fletchinger, T. C., Bonfiglio, J. V., Mata, L., Nemesure, M. D., Bartels, L. E., Wang, R., Rigas, B., & Mackenzie, G. G. (2019). Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation. Carcinogenesis, 40(12), 1480-1491. https://doi.org/10.1093/carcin/bgz069